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A high prevalence of methicillin-resistant Staphylococcus aureus 
(MRSA) carriage at hospital readmission among previous MRSA 
carriers warrants screening and preemptive isolation precautions. 
The replacement of culture on chromogenic agar with rapid quan-
titative polymerase chain reaction for readmission screening reduces 
the number of unnecessary preemptive isolation-days by 54% (from 
6.88 to 3.14 isolation-days) and related costs by 45% (from US$113.2 
to US$62.1) for patients who test negative for MRSA. 
Infect Control Hosp Epidemiol 2008; 29:1077-1079 
Infections caused by methicillin-resistant Staphylococcus au-
reus (MRSA) are associated with adverse outcomes and in-
creased hospital costs.1 Guidelines and expert opinion rec-
ommend that, in addition to transmission precaution 
measures, MRSA-positive patients should be placed in single 
rooms or cohorted with similarly colonized patients.2 Pre-
vious MRSA carriage is the principal risk factor for carriage 
at hospital readmission and is responsible for a large pro-
portion of the institutional reservoir of MRSA patients.3"5 
Therefore, it is common practice to screen for previous car-
riers and to place them in preemptive isolation at hospital 
readmission while awaiting the results of screening.4 
Because of logistical problems, the cost of isolation, patient 
discomfort, and the potential loss of care, it is desirable to 
shorten the latency period between screening and reporting 
of the results. In hospitals where there are insufficient rooms 
for the isolation or cohorting of MRSA-positive patients, a 
lower prevalence of presumed MRSA colonization reduces 
the need to house MRSA carriers with noncarriers in rooms 
with multiple beds, and thus reduces the risk of transmission. 
The use of polymerase chain reaction (PCR) for screening 
can shorten this latency period considerably, more so than 
the use of culture on chromogenic agar. In our study, we 
quantified the impact on logistics and costs of replacing the 
use of culture on chromogenic agar with the use of rapid 
multiplex quantitative PCR (qPCR)6,7 for the screening of 
previous MRSA carriers at hospital admission. 
METHODS 
Setting. The University of Geneva Hospitals, a 2,200-bed 
tertiary healthcare center, had 48,073 admissions in 2006. 
Previous MRSA carriers are flagged by a computerized rapid 
alert system.4 Our study was conducted in the general internal 
medicine service, which has 246 acute care beds, 9,249 annual 
admissions, and an average length of stay of 9.4 days. Ac-
cording to an audit in December 2006,25% of MRSA-positive 
patients were isolated in single rooms, 24% were in rooms 
with noncarriers, and 51% were cohorted in rooms with ei-
ther 2 or 6 beds. 
Study procedures. During 2 separate 90-day periods, all 
patients admitted to the hospital who were previous MRSA 
carriers were included in our study, independent of their 
length of hospitalization. The intervention period (from Sep-
tember 23 to December 21, 2006) differed from the control 
period (from January 1 to March 31, 2006) in the microbi-
ological method used to process screening samples. During 
the intervention period, use of culture on chromogenic agar 
(MRSA ID; bioMerieux), which was the microbiological 
method normally used for MRSA screening, was replaced by 
the use of qPCR.6 During both periods, samples were obtained 
on 2 consecutive days from the anterior nares and the groin 
using a cotton swab moistened with sterile saline solution. 
The main outcome variable was the number of unnecessary 
preemptive isolation-days among previous MRSA carriers 
who tested negative on readmission. The average cost for 1 
isolation-day, including the use of 10 gowns and 10 pairs of 
gloves and assuming a nursing severity score of 3 points, was 
estimated at a very conservative US$15 for each patient. To 
account for the different proportions of MRSA-negative pa-
tients during both periods, we assessed the number of iso-
lation-days and the other costs incurred during the inter-
vention period both in absolute numbers and by simulating 
the use of a chromogenic culture method for the intervention-
period population. 
All patients with previous MRSA carriage were placed in 
single rooms or cohorted, if logistically feasible; otherwise, 
barrier precautions were applied to patients sharing a room 
with noncarriers. Preemptive isolation was stopped on the 
day that both admission samples were reported to have neg-
ative results. Decolonization (ie, nasal mupirocin treatment 
twice daily for 5 days and whole-body washing with chlor-
hexidine soap for 7 days) was performed for all patients who 
had screening results positive for MRSA and was repeated if 
unsuccessful. 
RESULTS 
Overall, 1,583 hospital admissions accounted for 16,396 pa-
tient-days during the control period, and 1,942 hospital ad-
missions accounted for 20,060 patient-days during the in-
tervention period. For patients with MRSA carriage, there 
were a total of 1,570 isolation-days during the control period 
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T A B L E . Data on Patients Screened for Methicillin-Resistant Staphylococcus aureus (MRSA) 
Carriage Using 2 Different Screening Tests for 2 Separate Periods 
No. of No. of Screening Isolation Overall 
Period, patient group patients isolation-days cost, US$ cost, US$ cost, US$ 
Control period" 
MRSA positive 
MRSA negative 
Total 
Intervention periodb 
MRSA positive 
MRSA negative 
Total 
Simulated intervention period' 
MRSA positive 
MRSA negative 
Total 
82 
73 
155 
63 
113 
176 
63 
113 
176 
930 
502 
1,432 
1,132 
355 
1,487 
1,132 
777 
1,909 
820 
730 
1,550 
945 
1,695 
2,640 
630 
1,130 
1,760 
13,950 
7,530 
21,480 
16,980 
5,325 
22,305 
16,980 
11,655 
28,635 
14,770 
8,260 
23,030 
17,925 
7,020 
24,945 
17,610 
19,399 
30,395 
NOTE. Two consecutive screenings were performed for each patient. The average interval between admission 
and reporting of negative test results to the ward was 6.88 days (95% confidence interval, 6.41-7.35; median, 
7 isolation-days) during the control period and 3.14 days (95% confidence interval, 2.75-3.37; median, 3 
isolation-days) during the intervention period (P< .001; by 2-tailed x2 test). 
* Screening (from January 1 to March 31, 2006) by chromogenic agar culture, which was US$10 for each 
patient. 
b
 Screening (from September 23 to December 21, 2006) by in-house quantitative polymerase chain reaction 
(qPCR), which was estimated at a very conservative US$15 for each patient. For the use of commercial PCR 
(at US$70 per patient), the screening cost was estimated to be US$4,410 for MRSA-positive patients and 
US$7,910 for MRSA-negative patients, with an overall cost of US$34,625. 
c
 Simulation by use of chromogenic agar culture. 
and a total of 1,986 isolation-days during the intervention 
period. Data on the study patients are shown in the Table 
for the control and intervention periods. 
The average interval between admission and reporting of 
MRSA-negative results to the ward was 6.88 days (95% con-
fidence interval, 6.41-7.35; median, 7 isolation-days) during 
the control period and 3.14 days (95% confidence interval, 
2.75-3.37; median, 3 isolation-days) during the intervention 
period (P< .001; by 2-tailed x2 test), corresponding to a 
54.4% reduction in unnecessary isolation-days. Admission 
screening costs were US$10 for culture and US$15 for in-
house qPCR (US$5 and US$7.50 per test, respectively). The 
average cost per patient related to preemptive contact iso-
lation of previous MRSA carriers who tested negative for 
MRSA at readmission was 45% lower during the intervention 
period (US$62.10) than during the control period 
(US$113.20) (Figure). 
D I S C U S S I O N 
So far, the impact of screening known MRSA carriers at hos-
pital readmission by PCR has only been evaluated for inten-
sive care units, where this type of PCR screening reduced the 
number of isolation-days7 and the incidence of MRSA trans-
mission.8 Our study is the first, to our knowledge, to evaluate 
the impact of screening known MRSA carriers at hosptial 
readmission by qPCR, instead of in vitro culture, in acute 
care medicine wards, and the result was a reduction of a 
median of 4 isolation-days per patient and a reduction in 
related costs for previous MRSA carriers who tested negative 
at readmission. 
The duration of contact isolation was prolonged by the 
requirement that patients test negative for 2 separate samples 
D Screening • Isolation 
Control Intervention 
period period 
F I G U R E . Total estimated average cost per patient for screening and 
isolation for the control period (with screening by culture) and the 
isolation period (with screening by in-house quantitative polymerase 
chain reaction). 
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obtained on 2 consecutive days before contact isolation was 
stopped. By considering only the first screening by qPCR 
during the intervention period, we would have missed 7 pa-
tients (11% of all MRSA-positive patients) but would have 
saved an additional 126 isolation-days, with a possible det-
rimental impact on patient safety. 
The overall benefit of switching to a more rapid screening 
test depends on 3 key parameters: the number of patients at 
admission who are previous MRSA carriers; the proportion 
of these patients positive for MRSA; and the mean duration 
of contact isolation for MRSA-positive patients. The present 
real-life assessment demonstrates that these parameters may 
vary over time, even in the same hospital with the same policy 
for screening and contact isolation. Indeed, because of the 
higher number of study patients, in general, and the longer 
duration of contact isolation for MRSA-positive patients, in 
particular, the gross expenditure was slightly higher during 
the intervention period. To control for these confounders, we 
simulated the use of the chromogenic culture method for the 
intervention period population. In this simulation model, the 
use of qPCR resulted in an overall reduction in the number 
of isolation-days (422 [22.1%] of 1,909 isolation-days were 
saved) and in total cost (US$5,450 [17.9%] of US$30,395 
were saved). 
Our PCR cost estimates were based on use of an in-house 
PCR assay. However, most hospitals use commercial PCR 
assays, which may cost US$28-US$42. Considering an "av-
erage" PCR at US$35 per test, we found that the simulated 
costs would have risen by 13.9% if 2 PCR screenings were 
performed (Table) but would still have been reduced by 3.6% 
if only a single PCR test (with a single culture) was performed, 
which better corresponds to the reality in many hospitals. 
The cost of isolation may vary according to the hospital 
setting. Our cost estimates are very conservative. For a neo-
natal intensive care unit, Karchmer et al.9 reported minimal 
costs of US$30 per isolation-day for material (ie, gloves, 
gowns, and masks) and time. 
Since the introduction of our in-house qPCR, its sensitivity 
has been shown to be 96%, its specificity 91%, and its negative 
predictive value more than 99%, compared with the standard 
culture technique (unpublished data). Similarly, widely used 
commercial tests showed negative predictive values greater 
than 97%.8ao 
Because of the logistic and financial challenges for hospitals 
to control MRSA, it might be worth introducing PCR for 
MRSA screening, in addition to the promotion of hand hy-
giene, efficacious contact isolation, and better decolonization 
procedures. Because the introduction of PCR depends on 
several parameters, each institution should individually eval-
uate the possible benefits in advance. Currently, we are ex-
tending the use of qPCR to other sectors of our healthcare 
facility for the screening of previous MRSA carriers at hospital 
readmission. 
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